Formycon and Fresenius Kabi Report the MHRA’s Approval of Otulfi (Biosimilar, Stelara)

Shots: The UK’s MHRA has approved Otulfi (SC & IV), biosimilar of J&J’s Stelara (ustekinumab), to treat mod. to sev. active Crohn's disease, ulcerative colitis, plaque psoriasis as well as active psoriatic arthritis & is set to enter UK market as per a confidential settlement b/w the companies and J&J. It is approved across the US,…

BySenior EditorJanuary 16, 2025

News

Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

Shots: The P-I clinical trial evaluates the safety & efficacy of RT-111 in delivering CT-P43 (biosimilar, ustekinumab) in patients with moderate to severe plaque psoriasis, active psoriatic arthritis & IBD As per the results, RT-111 delivered CT-P43 in a dose proportional manner with high bioavailability & depicted a higher Cmax & shorter Tmax vs ustekinumab…

ByDipanshu DixitFebruary 3, 2024

INSIGHTS+

Disease of the Month – Ulcerative Colitis

Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Continuing the series for the disease of the month, PharmaShots presents a condensed report on Ulcerative Colitis, which causes inflammation and sores (ulcers) in the digestive…

BySenior EditorNovember 28, 2023

VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…

BySenior EditorNovember 24, 2021

VIEWPOINTS

PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD

In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBD Shots: CTMA developed the web mobile platform, CT-Scout to boost patient recruitment in the clinical trials by facilitating a quick and simple study detection for eligible patients CT-Scout is currently available in…

BySenior EditorOctober 11, 2021

Formycon and Fresenius Kabi Report the MHRA’s Approval of Otulfi (Biosimilar, Stelara)

Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

Disease of the Month – Ulcerative Colitis

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD

Contact US

OUR INFORMATION

FOLLW US

Formycon and Fresenius Kabi Report the MHRA’s Approval of Otulfi (Biosimilar, Stelara)

Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

Disease of the Month – Ulcerative Colitis

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD

FOLLW US

Sign Up to Our Newsletter